Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis

Conclusions
Primary adjunctive high-dose 10 mg/kg infliximab treatment was associated with a greater likelihood of CAA regression in patients with CAA at the time of diagnosis.

Source: Archives of Disease in Childhood - September 19, 2023 Category: Pediatrics Authors: Miyata, K., Bainto, E. V., Sun, X., Jain, S., Dummer, K. B., Burns, J. C., Tremoulet, A. H. Tags: Open access Original research Source Type: research